Half-year report · Q2
2372.TEDINET S100UMR9
Period2024-04-01 → 2024-09-30
Filed2024-11-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥17.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥85m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥790m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥75m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥52m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥65m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥65m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥35.3bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥37.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥36.2bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥22.7bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥24.4bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥12.6bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥12.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥13.0bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.4bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥446m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥803m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥280m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥163m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥17m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-5.41 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥116.92 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.22 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.8% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.4% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 63
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥95m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥969m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥597m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥554m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥101m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥344m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥41m |
| jpcrp040300-q2r_E05352-000Drug Discovery Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥229m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥506m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥626m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥95m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥320m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.4bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥8.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥250m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥219m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥31m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥25m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥913m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥884m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥887m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥20m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥610m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥66m |
| jpcrp040300-q2r_E05352-000Drug Discovery Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥367m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥903m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥494m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥409m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥39m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥490m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.1bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.9bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥8.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥11.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 551
| Item | Context | Value | Unit |
|---|---|---|---|
| Income before income taxes | CurrentYTDDuration | 52000000 | JPY |
| Income taxes current | Prior1YTDDuration | 280000000 | JPY |
| Income taxes current | CurrentYTDDuration | 141000000 | JPY |
| Income taxes deferred | Prior1YTDDuration | 41000000 | JPY |
| Income taxes deferred | CurrentYTDDuration | -24000000 | JPY |
| Income taxes | Prior1YTDDuration | 322000000 | JPY |
| Income taxes | CurrentYTDDuration | 117000000 | JPY |
| Profit loss | Prior1YTDDuration | 1092000000 | JPY |
| Profit loss | CurrentYTDDuration | -65000000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 1092000000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | -65000000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YTDDuration | -0 | JPY |
| Profit loss attributable to non controlling interests | CurrentYTDDuration | － | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | 78000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | -77000000 | JPY |
| Foreign currency translation adjustment net of tax oci | Prior1YTDDuration | -1000000 | JPY |
| Foreign currency translation adjustment net of tax oci | CurrentYTDDuration | 16000000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 77000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | -60000000 | JPY |
| Comprehensive income | Prior1YTDDuration | 1169000000 | JPY |
| Comprehensive income | CurrentYTDDuration | -126000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 1169000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | -126000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | -0 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | － | JPY |
| Income before income taxes | Prior1YTDDuration | 1414000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 52000000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 463000000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 540000000 | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 60000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 60000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -8000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -19000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 85000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 103000000 | JPY |
| Foreign exchange losses gains ope cf | Prior1YTDDuration | -481000000 | JPY |
| Foreign exchange losses gains ope cf | CurrentYTDDuration | 225000000 | JPY |
| Loss gain on securities operation ope cf | Prior1YTDDuration | 56000000 | JPY |
| Loss gain on securities operation ope cf | CurrentYTDDuration | -80000000 | JPY |
| Loss gain on sales of investment securities ope cf | Prior1YTDDuration | － | JPY |
| Loss gain on sales of investment securities ope cf | CurrentYTDDuration | -61000000 | JPY |
| Loss gain on sales of noncurrent assets ope cf | Prior1YTDDuration | -193000000 | JPY |
| Loss gain on sales of noncurrent assets ope cf | CurrentYTDDuration | -128000000 | JPY |
| Subsidy income2 ope cf | Prior1YTDDuration | -43000000 | JPY |
| Subsidy income2 ope cf | CurrentYTDDuration | -31000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | 291000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | 873000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -37000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -40000000 | JPY |
| Decrease increase in deposits paid ope cf | Prior1YTDDuration | -33000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |